DanCann Pharma is a Danish life science company focused on discovering, developing, manufacturing, and commercialization of novel cannabinoid therapeutic products for medical use. The company was founded in 2018 due to the poor access for cannabinoid-based drugs and pharmaceuticals and with the purpose of developing and supplying medical cannabis, with a focus on consistency and quality provided by state-of-the-art and newly constructed manufacturing facilities (called Biotech Pharm1) which expect to be approved by the Danish authorities during 2022. DanCann recently acquired the Danish distributor of medical cannabis products, CannGros after which DanCann is now a fully vertical integrated operator within the market of cannabis for medical use, having development, manufacturing, and commercialization capabilities in-house.